VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ 18 years of age or older                           │ 18 years of age or older                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have one of the following disease histories        │ Have one of the following disease histories        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Residual clinically or radiographically evident    │ Residual clinically or radiographically evident    │     100 │
│ tumor, including primary cutaneous and mucosal     │ tumor, including primary cutaneous and mucosal     │         │
│ melanomas                                          │ melanomas                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior radiation therapy, chemotherapy, or surgery  │ Prior radiation therapy, chemotherapy, or surgery  │     100 │
│ in patients requiring flap reconstruction in the   │ in patients requiring flap reconstruction in the   │         │
│ head and neck region                               │ head and neck region                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ All patients of childbearing and child-creating    │ All patients of childbearing and child-creating    │     100 │
│ age must be using an acceptable form of birth      │ age must be using an acceptable form of birth      │         │
│ control                                            │ control                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pre-menopausal must have a negative  │ Women who are pre-menopausal must have a negative  │     100 │
│ serum pregnancy test                               │ serum pregnancy test                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known pregnancy or breast-feeding                  │ Known pregnancy or breast-feeding                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical illness unrelated to the tumor which in    │ Medical illness unrelated to the tumor which in    │     100 │
│ the opinion of the attending physician and         │ the opinion of the attending physician and         │         │
│ principal investigator will preclude               │ principal investigator will preclude               │         │
│ administration of the agent. This includes         │ administration of the agent. This includes         │         │
│ patients with uncontrolled infection, chronic      │ patients with uncontrolled infection, chronic      │         │
│ renal insufficiency, myocardial infarction within  │ renal insufficiency, myocardial infarction within  │         │
│ the past 6 months, unstable angina, cardiac        │ the past 6 months, unstable angina, cardiac        │         │
│ arrhythmias other than chronic atrial fibrillation │ arrhythmias other than chronic atrial fibrillation │         │
│ and chronic active or persistent hepatitis, or New │ and chronic active or persistent hepatitis, or New │         │
│ York Heart Association Classification III or IV    │ York Heart Association Classification III or IV    │         │
│ heart disease                                      │ heart disease                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At the discretion of the physician or surgeon,     │ At the discretion of the operating surgeon,        │      95 │
│ bilirubin level of \< 2.0 mg/dl in the absence of  │ Bilirubin level of < 2.0 mg/dl in the absence of a │         │
│ a history of Gilbert's disease (or pattern         │ history of Gilbert's disease (or pattern           │         │
│ consistent with Gilbert's)                         │ consistent with Gilbert's)                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Newly diagnosed patients with previous excisional  │ Newly diagnosed patients with previous excisional  │      97 │
│ biopsy                                             │ biopsy. OR                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At the discretion of the operating surgeon,        │ At the discretion of the operating surgeon,        │      99 │
│ ANC\>1000/mcl and platelets\>100,000/mcl           │ ANC>1000/mcl and platelets>100,000/mcl             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For melanoma patients, if patients have a history  │ For melanoma patients, If patients have a history  │      99 │
│ of malignancy other than melanoma, and other skin  │ of malignancy other than melanoma, and other skin  │         │
│ cancers in the past five years, their inclusion is │ cancers in the past five years, their inclusion is │         │
│ up to the discretion of the physician              │ up to the discretion of the physician              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                    │   Score │
╞════════════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ 18 years of age or older                         │      42 │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ At the discretion of the physician or surgeon,     │ Normal baseline cardiac function based upon pre- │      73 │
│ normal baseline cardiac function based upon pre-   │ operative evaluation                             │         │
│ operative evaluation                               │                                                  │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Histologically confirmed diagnosis of melanoma at  │ Histologically confirmed diagnosis of melanoma,  │      75 │
│ MSKCC                                              │ breast cancer or gynecologic cancer at MSKCC     │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Newly-diagnosed or recurrent (local, regional,     │ Newly-diagnosed or recurrent (local, regional,   │      79 │
│ metastatic) malignant melanoma, oral cavity        │ metastatic) malignant melanoma or breast cancer  │         │
│ squamous cell carcinoma, and squamous cell         │ patients in whom SLN mapping is indicated        │         │
│ carcinoma of the skin patients in whom SLN mapping │                                                  │         │
│ is indicated                                       │                                                  │         │
╘════════════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                    │   Score │
╞════════════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Newly diagnosed patients with previous excisional  │ Newly-diagnosed gynecologic cancer patients in   │      54 │
│ biopsy                                             │ whom SLN mapping and surgical excision is        │         │
│                                                    │ indicated OR                                     │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ At the discretion of the physician or surgeon,     │ Normal baseline cardiac function based upon pre- │      73 │
│ normal baseline cardiac function based upon pre-   │ operative evaluation                             │         │
│ operative evaluation                               │                                                  │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Histologically confirmed diagnosis of melanoma at  │ Histologically confirmed diagnosis of melanoma,  │      75 │
│ MSKCC                                              │ breast cancer or gynecologic cancer at MSKCC     │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Newly-diagnosed or recurrent (local, regional,     │ Newly-diagnosed or recurrent (local, regional,   │      79 │
│ metastatic) malignant melanoma, oral cavity        │ metastatic) malignant melanoma or breast cancer  │         │
│ squamous cell carcinoma, and squamous cell         │ patients in whom SLN mapping is indicated        │         │
│ carcinoma of the skin patients in whom SLN mapping │                                                  │         │
│ is indicated                                       │                                                  │         │
╘════════════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 93
Average Levenshtein Ratio of individual lines: 87.0
OverAll Ratio: 90.0
